Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Physiomics ( (GB:PYC) ) just unveiled an announcement.
Physiomics plc announced the joint publication of a peer-reviewed article with Merck KGaA, showcasing a mathematical model to optimize combination oncology therapies. The publication highlights how Physiomics’ Virtual Tumour platform accelerates drug development by predicting effective experimental permutations, mitigating costs, and informing clinical trial designs. This collaboration underscores the company’s influential role in the development of innovative oncology treatments and its strong, longstanding partnership with Merck KGaA.
More about Physiomics
Physiomics plc is a leading company in the field of mathematical modelling, data science, and biostatistics, primarily focusing on the development of therapeutic solutions and personalized medicine. The company utilizes its expertise to assist biotech and pharma companies in optimizing their drug development processes, leveraging advanced computational tools and proprietary technologies like their Virtual Tumour platform.
YTD Price Performance: 46.67%
Average Trading Volume: 4,012,991
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £2.08M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.
